News | May 11, 2023
Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 125.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
